Q-omics provides the consensus-scored TG profile across patient tissues and cancer cell-line models. TG expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TG is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TG RNA expression shows 14,942 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where TG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TG survival associations across molecular data types. TG RNA expression shows survival associations in the most cancer types (23), followed by mutation status (12) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TG RNA expression–survival associations across cancer types. High TG expression shows unfavorable associations in ACC and LUAD, but favorable associations in LIHC, READ, COAD and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TG RNA expression.
This table summarizes TG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TG shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD, BRCA, KICH and LUSC. The THCA box plot shows higher TG RNA expression in normal versus tumor tissue (log2 FC = −3.755, t-test p < 0.001).
This table shows molecular features associated with TG in patient tissues and cancer cell lines. In patient samples, TG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
